Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived

Cancer Discov. 2018 Jul;8(7):797-799. doi: 10.1158/2159-8290.CD-18-0489.

Abstract

BLU-667 is a next-generation RET inhibitor that maximizes on-target and minimizes off-target effects. It is an exemplar of genotype-driven drug development followed by multi-histology basket trial validation that is becoming a paradigm for precision oncology. Cancer Discov; 8(7); 797-9. ©2018 AACRSee related article by Subbiah et al., p. 836.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Medical Oncology
  • Neoplasms*
  • Precision Medicine
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-ret

Substances

  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-ret
  • RET protein, human